The 15 references in paper P. LAGUTA S., E. PANCHENKO P., П. ЛАГУТА С., Е. ПАНЧЕНКО П. (2017) “МЕСТО ПРАСУГРЕЛА СРЕДИ ДРУГИХ ИНГИБИТОРОВ P2Y12-РЕЦЕПТОРОВ ТРОМБОЦИТОВ // NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS” / spz:neicon:aterotromboz:y:2017:i:2:p:43-52

1
Мазуров А.В. Физиология и патология тромбоцитов. «Литтерра» 2011, 480 стр.
(check this in PDF content)
2
Kei AA, Florentin M et. al. Antiplatelet Drugs: What comes next? Clinical and Applied Thrombosis. Hemostasis,2011, 17(1): 9-26.
(check this in PDF content)
3
Wiviott SD, Braunwald E et al. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med., 2007, 357: 2001-2015.
(check this in PDF content)
4
Morrow DA, Wiviott SD et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation,2009, 119: 2758-2764.
(check this in PDF content)
5
Wiviotti SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind,randomised controlled trial.Lancet,2009, 373: 723–31.
(check this in PDF content)
6
Wiviotti SD, Braunwald E et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet, 2008, 371: 1353–63.
(check this in PDF content)
7
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J., 2017, 00: 1–66.
(check this in PDF content)
8
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). 59p.
(check this in PDF content)
9
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal,2017, 0: 1–48.
(check this in PDF content)
10
Montalescot G, Bolognese L et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N. Engl. J. Med.,2013, 369: 999–1010.
(check this in PDF content)
11
Roe MT, Armstrong PW, Fox KA et al. Trilogy ACS Investigators. Prasugrel versus clopidogrel for the acute coronary syndromes without revascularisation. N. Engl. J. Med., 2012, 367(4): 1297-1309.
(check this in PDF content)
12
James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO) Trial. Br. Med. J., 2011, 342: 3527.
(check this in PDF content)
13
Mauri L, Kereiakes DJ, Yeh RW et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med., 2014, 371: 2155–2166.
(check this in PDF content)
14
Garratt KN, Weaver WD, Jenkins RG et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS LiberteЂpaclitaxeleluting coronary stent placement. Circulation,2015, 131: 62–73.
(check this in PDF content)
15
Bonaca MP, Bhatt DL, Cohen M et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med., 2015, 372: 1791–1800.
(check this in PDF content)